Tests a stomach lining procedure in adults with obesity after stopping GLP-1 drugs
Tests a stomach lining procedure in adults with obesity who stop semaglutide or tirzepatide.
Key facts
- Who runs it
- Dr. Christopher McGowan
- Where
- Cary, United StatesSee the site
- Trial code
- Registry title
- MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 1 Jan 2025
- Planned end
- Jun 2026
- Type of study
- Interventional
- Treatments tested
- Gastric Fundal Mucosal Ablation (GFMA)
- Record updated
- 21 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity who lost at least 10% of their body weight on semaglutide or tirzepatide and have stopped, or plan to stop, the drug.
- Age
- 21 to 65 years
- Sex
- All sexes
- Disease stage
- Obesity with a BMI of ≥30 kg/m² or ≤45 kg/m². No history of diabetes. Did not regain more than 50% of the lost weight after stopping the drug.
- Earlier treatment
- Must have lost ≥10% of total body weight on semaglutide or tirzepatide taken for obesity, at a stable dose for at least 12 weeks. Must have stopped it or plan to stop it, with no more than 24 weeks since the last dose.
- Biomarker or test result
- Hemoglobin A1c must not be above 6.5% (48 mmol/mol) at screening.
Main reasons for not taking part
- Type 1 or type 2 diabetes
- Blood thinners or NSAIDs that cannot be stopped for 12 weeks
- Active H. pylori infection or an untreated past infection, or an active stomach ulcer
- Gastroparesis, functional dyspepsia or active disordered eating
- Pregnant, planning pregnancy, or refusing effective birth control
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Subjects aged 21-65
- Body mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≤45 kg/m²
- Observed ≥ 10% TBWL with semaglutide or tirzepatide use for primary obesity therapy
- Subject did not experience >50% weight recurrence since discontinuation of semaglutide or tirzepatide
- Maintained a stable dose of semaglutide or tirzepatide for a minimum of 12 weeks
- Have recently discontinued or are planning to discontinue semaglutide or tirzepatide (≤ 24 weeks from last dose to time of study procedure)
- No previous medical history of diabetes mellitus
- Willing and able to participate in the study procedures
- Understand and voluntarily sign the informed consent
Who cannot take part
- Use of concomitant medications known to induce weight loss (including but not limited to liraglutide, phentermine, phentermine/topiramate, bupropion/naltrexone, metformin)
- Use of GLP-1 or GLP-1/GIP medication for the treatment of diabetes, rather than obesity
- Known bleeding diathesis that cannot be corrected through medical means
- History of decompensated end-organ disease
- History of any stomach manipulation (including repair of hiatal hernia or fundoplication) deemed unsafe by PI for GFMA
- Active H. pylori infection or history of H pylori without treatment and confirmation of eradication
- Known diagnosis of type I or type II diabetes or a Hemoglobin A1c > 6.5% at time of screening
- Patients on any medications or supplements including those that may influence cholecystokinin (CCK), glucose, growth hormone, insulin and/or somatostatin levels
- Use of anticoagulation, antithrombotic agents, and/or NSAIDs that cannot be discontinued for a minimum of 12 weeks
- Unwillingness to abstain from the use of incretin mimetics during the study duration
- Unwillingness to abstain from the use of tobacco during the study duration
- Active disordered eating
- Patients who do not give their consent to the enrollment in the study or are incompetent, unconscious or unable to express their consent for any reason
- Known diagnosis of gastroparesis or functional dyspepsia
- Patients who are pregnant, who plan to become pregnant during study duration, or patients of child-bearing potential who refuse effective birth control methods (as approved by PI)
- Active gastric ulceration
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 65 years old?
Where in United States
- True You Weight LossCary, United StatesContact: Chase Wooley, BSNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this study is to assess the effect of gastric fundal mucosal ablation (GFMA) on weight trajectory following discontinuation of once-weekly semaglutide or tirzepatide in adults with obesity. In this study, GFMA will be performed on patients who have experienced > 10% weight loss with GLP-1 therapy and who plan to discontinue use of GLP-1 medications for the duration of the study.
The group in the trial
- Gastric Fundal Mucosal Ablation (GFMA) following discontinuation of GLP-1 therapyTreatment being tested
Subjects will undergo endoscopic Gastric Fundal Mucosal Ablation (GFMA) following following discontinuation of GLP-1 therapy. This will be performed by an experienced endoscopist specialized in bariatric endoscopy in a single endoscopic session.
Treatment: Gastric Fundal Mucosal Ablation (GFMA)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Gastric Fundal Mucosal Ablation for Weight Management in Patients Stopping Glucagon-like Peptide-1 Receptor Agonists
- Plain-language title
- Tests a stomach lining procedure in adults with obesity after stopping GLP-1 drugsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06734312, who can take part
- Record updated
- 21 March 2025